2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1932

Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease
Abstract Number: 776

Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma
Abstract Number: 2024

Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus
Abstract Number: 1942

Genome-wide Association Study in a Japanese Population Revealed Novel Candidate Genes for Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Abstract Number: 1050

Genome-Wide DNA Methylation Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis
Abstract Number: 1718

Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017
Abstract Number: 2917

Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
Abstract Number: 2658

Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries
Abstract Number: 2670

Giant Cell Arteritis with Intracranial Vasculitis: A Case Series
Abstract Number: 2659

Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case–Control Study
Abstract Number: 1995

Gingival-Derived Mesenchymal Stem Cells Alleviate Cartilage Damage in Collagen-Induced Arthritis via Suppressing Activities of Inflamed Synovial Fibroblast
Abstract Number: L16

GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study
Abstract Number: 416

Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
Abstract Number: 1379

Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Abstract Number: 1383

Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].